Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 167

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 9C
Chunk 167
---
requisite service periods using the straight-line method. The Company has elected to account for forfeiture of stock-based awards as
they occur.

    F-9

Telomir
                                            Pharmaceuticals, Inc.

notes
to the financial statements

DECEMBER
31, 2024 and  2023

Fair
Value Measurements and Financial Instruments

The
Company measures the fair value of financial instruments in accordance with GAAP which defines fair value, establishes a framework for
measuring fair value, and expands disclosures about fair value measurements.

GAAP
defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
GAAP also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use
of unobservable inputs when measuring fair value. The Company considers the carrying amount of deferred offering costs to approximate
fair value due to short-term nature of this instrument. GAAP describes three levels of inputs that may be used to measure fair value:

Level
1 – quoted prices in active markets for identical assets or liabilities.

Level
2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable.

Level
3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions).

Earnings
per Share

Earnings
(loss) per share is computed in accordance with ASC Topic 260, “Earnings per Share” Basic weighted-average number of
shares of common stock outstanding for the year ended December 31, 2024 and December 31, 2023 include the shares of the Company
issued and outstanding during such period, on a weighted average basis. The basic weighted average number of shares of common stock
outstanding excludes common stock equivalents such as stock options and warrants, while diluted weighted average number of shares
outstanding includes such stock options and warrants. As of December 31, 2024 there were 2,814,057
stock warrants and 2,352,670
stock options that were not included in the computation of diluted earnings per share, because to do so would have an antidilutive
effect. As of December 31, 2023 there was 2,774,057
stock warrants that were not included in the computation of diluted earnings per share, because to do so would have an antidilutive
effect